New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases

被引:52
作者
Mascolo, A. [1 ]
Sessa, M. [1 ]
Scavone, C. [1 ]
De Angelis, A. [1 ]
Vitale, C. [2 ]
Berrino, L. [1 ]
Rossi, F. [1 ]
Rosano, G. [2 ,3 ]
Capuano, A. [1 ]
机构
[1] Univ Naples 2, Sect Pharmacol L Donatelli, Dept Expt Med, Via L de Crecchio 7, I-80138 Naples, Italy
[2] IRCCS San Raffaele Pisana, Rome, Italy
[3] St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England
关键词
Pharmacology; Angiotensin; Renin-angiotensin-aldosterone system; Heart failure; Coronary artery disease; Neurological diseases; CONVERTING ENZYME 2; MINERALOCORTICOID RECEPTOR ANTAGONIST; AMINOPEPTIDASE-A INHIBITORS; OXIDATIVE STRESS STATUS; INDUCED HYPERTENSION; BINDING-SITE; (PRO)RENIN RECEPTOR; DOUBLE-BLIND; INTRACEREBROVENTRICULAR INFUSION; SYMPATHETIC HYPERACTIVITY;
D O I
10.1016/j.ijcard.2016.10.069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is commonly accepted that the renin-angiotensin-aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood-brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS. (c) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:734 / 742
页数:9
相关论文
共 108 条
[1]   ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer's Disease [J].
AbdAlla, Said ;
Langer, Andreas ;
Fu, Xuebin ;
Quitterer, Ursula .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (08) :16917-16942
[2]   Nitric oxide impacts on angiotensin AT2 receptor modulation of high- pressure baroreflex control of renal sympathetic nerve activity in anaesthetized rats [J].
Abdulla, M. H. ;
Johns, E. J. .
ACTA PHYSIOLOGICA, 2014, 210 (04) :832-844
[3]   Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats [J].
Ali, Quaisar ;
Patel, Sanket ;
Hussain, Tahir .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2015, 308 (12) :F1379-F1385
[4]   INHIBITION OF BRAIN RENIN-ANGIOTENSIN SYSTEM IMPROVES DIASTOLIC CARDIAC FUNCTION FOLLOWING MYOCARDIAL INFARCTION IN RATS [J].
Araujo, I. G. ;
Trindade, D. C. ;
Mecawi, A. S. ;
Sonoda-Cortes, Rafael ;
Werneck-de-Castro, J. P. S. ;
Costa-e-Sousa, R. H. ;
Reis, L. C. ;
Olivares, E. L. .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2009, 36 (08) :803-809
[5]   The brain renin-angiotensin system and cardiovascular responses to stress: insights from transgenic rats with low brain angiotensinogen [J].
Arnold, Amy C. ;
Sakima, Atsushi ;
Kasper, Sherry O. ;
Vinsant, Sherry ;
Garcia-Espinosa, Maria Antonia ;
Diz, Debra I. .
JOURNAL OF APPLIED PHYSIOLOGY, 2012, 113 (12) :1929-1936
[6]   Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug [J].
Balavoine, Fabrice ;
Azizi, Michel ;
Bergerot, Damien ;
De Mota, Nadia ;
Patouret, Remi ;
Roques, Bernard P. ;
Llorens-Cortes, Catherine .
CLINICAL PHARMACOKINETICS, 2014, 53 (04) :385-395
[7]   The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy [J].
Baltatu, O ;
Silva, JA ;
Ganten, D ;
Bader, M .
HYPERTENSION, 2000, 35 (01) :409-412
[8]   Facilitation of Hippocampal Synaptogenesis and Spatial Memory by C-Terminal Truncated Nle1-Angiotensin IV Analogs [J].
Benoist, Caroline C. ;
Wright, John W. ;
Zhu, Mingyan ;
Appleyard, Suzanne M. ;
Wayman, Gary A. ;
Harding, Joseph W. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01) :35-44
[9]  
Berecek K H, 1984, J Hypertens Suppl, V2, pS63
[10]   An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats [J].
Bertagnolli, Mariane ;
Casali, Karina R. ;
De Sousa, Frederico B. ;
Rigatto, Katya ;
Becker, Lenice ;
Santos, Sergio H. S. ;
Dias, Lucinara D. ;
Pinto, Graziela ;
Dartora, Daniela R. ;
Schaan, Beatriz D. ;
Sinisterra Milan, Ruben Dario ;
Irigoyen, Maria Claudia ;
Santos, Robson A. S. .
PEPTIDES, 2014, 51 :65-73